Blog dedicated to the continuous education in Gynecology and Endocrinology

 

Serum vitamin B12 and homocysteine levels in pregnant women with neural tube defect

Ceyhan – DGYE-2009-0164.r1 [ID 463727]

Abstract: Objective: Aim of the study is to investigate the importance of serum vitamin B12 levels in pregnants with fetal neural tube defect.
Study Design: This study consists of 31 pregnant women having fetuses with neural tube defect. more

Post to Twitter Post to Facebook

Perceived control over menopausal hot flushes in mid-aged women

Chedraui DGYE-2009-0236 [ID 463737]

Objective. To assess perceived control over menopausal HFs and determinant factors among mid-aged Ecuadorian women.
Methods. Healthy women aged 40 to 59 years were assessed with the Menopause Rating Scale (MRS) and those presenting HFs were requested to fill out the Perceived Control Index (PCI) and more

Post to Twitter Post to Facebook

Premature ovarian failure from current perspective

Kokcu, Arif DGYE-2010-0038[488773]

Premature ovarian failure is a syndrome characterized by amenorrhea, hypoestrogenism, and hypergonadotropinism before the age of 40. It is a disorder affecting approximately 1% of women <40 years, 1/1.000 women by the age of 30 and 1/10.000 women by the age of 20. POF is not merely an early menopause. more

Post to Twitter Post to Facebook

Original Paper High internal consistency and efficacy of intravaginal DHEA for vaginal atrophy.

Labrie, Fernand (contact); Archer, D; Bouchard, Céline; Fortier, Michel; Cusan, Leonello; Gomez, José-Luis; Girard, Ginette; Baron, Mira; Ayotte, Normand; Moreau, Michèle; Dubé, Robert; Côté, Isabelle; Labrie, Claude; Lavoie, Lyne; Berger, Louise; Martel, Céline; Balseer, John DGYE-2009-0199[451587] 9PAG

Following the compelling data obtained in a pivotal phase III clinical trial performed in 218 postmenopausal women suffering from vaginal atrophy who received daily intravaginal 0.25%, 0.5% or 1.0% DHEA ovules for 12 weeks, we have performed analysis of the 4 co-primary objectives at each site of that multicenter U.S. and Canadian trial. Comparison was made of the change in % of parabasal and superficial cells, vaginal pH and severity of the most bothersome symptom. more

Post to Twitter Post to Facebook

Assessing fatal cardiovascular disease risk with the SCORE scale in postmenopausal women 10 years after different hormone treatment regimens

Faustino Prez-lopez DGYE-2009-0132.r1 [ID 436880] 6 pag

Objective. To assess fatal cardiovascular disease (FCD) risk among women in early postmenopausal years, as evaluated with the Systematic Coronary Risk Evaluation (SCORE) scale.
Design. This was a retrospective study of parallel cohorts. Two hundred seventy three healthy postmenopausal women. Participants received one of the following hormone treatment (HT) regimens: transdermal estradiol (50 µg) (n=99), sequential cyclic HT with transdermal estradiol (50 µg/day) plus 200 mg/day natural more

Post to Twitter Post to Facebook

© International Society of Gynecological Endocrinology - Privacy Policy